Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071324 | 0.80 | ALDH1A1 (0.40) | TDP1SMN1; SMN2MMEFOLH1RIMKLA | |
| SCHEMBL15731210 | 0.80 | SLC22A6 (0.36) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL27429676 | 0.80 | CA2 (0.34) | CA2CA4SMN1; SMN2MMEFOLH1 | |
| SCHEMBL22106724 | 0.80 | ECE1 (0.44) | CA2MAPT | |
| SCHEMBL14071766 | 0.80 | ECE1 (0.44) | CA2MAPT | |
| SCHEMBL6558713 | 0.79 | GNPAT (0.51) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL120136 | 0.79 | CA2 (0.55) | CA2CA4TDP1SMN1; SMN2MME | |
| SCHEMBL30235634 | 0.79 | CA2 (0.55) | CA2CA4TDP1SMN1; SMN2MME | |
| SCHEMBL14625014 | 0.79 | GNPAT (0.51) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL7080110 | 0.79 | GNPAT (0.51) | CA2CA4TDP1SMN1; SMN2SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465716-B2 | Targeted drug delivery with a hyaluronan ligand | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-16 | — | — | US | claimed |
| EP-1233754-A4 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | UNIV CALIFORNIA (US) | 2006-06-07 | — | — | EP | claimed |
| US-20030166602-A1 | A delivery vehicle low molecular weight hyaluronan ligand, glycosaminoglycan ligand for binding to antigen, with antitumor agents, or anticancer agents | SZOKA FRANCIS C (US) | 2003-09-04 | — | — | US | claimed |
| US-20020131995-A1 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | CALIFORNIA, UNIVERSITY OF THE, REGENTS OF, THE | 2002-09-19 | — | — | US | claimed |
| EP-1233754-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | The Regents of The University of California (US) | 2002-08-28 | — | — | EP | claimed |
| WO-2001039815-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-06-07 | — | — | WO | claimed |
| CN-121574249-A | Anti-CD 45 antibodies and conjugates thereof | VOR生物制药股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-121038787-A | Topical PALA therapy for cancer | 克利夫兰诊所基金会 | 2025-11-28 | — | — | CN | disclosed |
| CN-119816500-A | Crystalline forms of the irreversible menin-MLL inhibitor N- [4- [4- (4-morpholinyl) -7H-pyrrolo [2,3-d ] pyrimidin-6-yl ] phenyl ] -4- [ [3 (R) - [ (1-oxo-2-propen-1-yl) amino ] -1-piperidinyl ] methyl ] -2-pyridinecarboxamide for the treatment of cancer | 拜欧米富士恩公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-115611945-B | Water-soluble phosphoric acid derivative, preparation method thereof, pharmaceutical composition and application | 北京森妙生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119462640-A | Pyridine [3,2-d ] pyrimidine-2-amine derivative, and preparation method and application thereof | 北京森妙生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-114728972-B | Crystalline forms of a C-C chemokine receptor type 4 antagonist and uses thereof | 拉普特医疗公司 | 2024-12-10 | — | — | CN | disclosed |
| US-12005146-B2 | Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-7465716-B2 | Targeted drug delivery with a hyaluronan ligand | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1233754-A4 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | UNIV CALIFORNIA (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20030166602-A1 | A delivery vehicle low molecular weight hyaluronan ligand, glycosaminoglycan ligand for binding to antigen, with antitumor agents, or anticancer agents | SZOKA FRANCIS C (US) | 2003-09-04 | — | — | US | disclosed |
| US-6593308-B2 | Drug delivery system comprising delivery vehicle having low molecular weight hyaluronan ligand with affinity for CD44 receptors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-15 | — | — | US | disclosed |
| US-20020131995-A1 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | CALIFORNIA, UNIVERSITY OF THE, REGENTS OF, THE | 2002-09-19 | — | — | US | disclosed |
| EP-1233754-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | The Regents of The University of California (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001039815-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-06-07 | — | — | WO | disclosed |